Inhibition of SIRT1 was identified as a possible drug target in BRAF-altered CRC based on the c-Myc/NAMPT/SIRT1 feedback loop and c-Myc-mediated SIRT1 upregulation[135]. The gene discussed is NAMPT; the disease is colorectal carcinoma.